Consensus molecular subtyping improves the clinical usefulness of canonical tumor markers for colorectal cancer

Transcriptome-based classification, such as consensus molecular subtyping, is expected to be applied to colorectal cancer (CRC). However, the relationship between molecular profiles and classical tumor markers, which are already used in clinical practice, has not been analyzed in a large cohort and...

Full description

Saved in:
Bibliographic Details
Published in:Biomedical Research 2022/12/01, Vol.43(6), pp.201-209
Main Authors: KAGAWA, Hiroyasu, HATAKEYAMA, Keiichi, SHIOMI, Akio, HINO, Hitoshi, MANABE, Shoichi, YAMAOKA, Yusuke, NAGASHIMA, Takeshi, OHSHIMA, Keiichi, URAKAMI, Kenichi, YAMAGUCHI, Ken
Format: Article
Language:English
Subjects:
Antigens
Biomarkers
Biomarkers, Tumor - genetics
Blood
Cancer
Carcinoembryonic antigen
Carcinoembryonic Antigen - genetics
Carcinoembryonic Antigen - therapeutic use
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - diagnosis
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Decision analysis
Gene expression
Humans
Mutation
Prognosis
Subgroups
Transcriptome
Transcriptomes
Tumor markers
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Transcriptome-based classification, such as consensus molecular subtyping, is expected to be applied to colorectal cancer (CRC). However, the relationship between molecular profiles and classical tumor markers, which are already used in clinical practice, has not been analyzed in a large cohort and remains unclear. We classified more than 1,500 Japanese patients with CRC based on consensus molecular subtyping and investigated the clinically available blood carcinoembryonic antigen (CEA) concentrations of each subgroup. To precisely distinguish CRCs, we allocated them to five subgroups, including tumors that were difficult to classify using the consensus molecular subtypes (CMSs), and extracted a heterogeneous population with somatic mutations and expression profiles that differed from those of the CMSs 1–4. For patients allocated to the CMS4 subgroup of stage III CRCs, elevated blood CEA concentrations may identify a subgroup with highly aggressive disease and contribute to improving therapeutic decisions. Furthermore, gene expression and pathway analyses of tumor and non-tumor tissues revealed that tumor immunity was “cold” in this subgroup with high CEA concentrations. The combination of emerging molecular profiling and classical tumor markers may have greater clinical utility than either used alone.
ISSN:0388-6107
1880-313X
DOI:10.2220/biomedres.43.201